Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Retrospective single-center study of 87 patients identifying progression patterns as prognostic factors for post-progression survival in CDK4/6-inhibitor-treated HR+/HER2− metastatic breast cancer, with statistically significant hazard ratios for visceral and liver progression but limited by design and sample size.
This is a narrative review proposing a theoretical therapeutic strategy combining LZK-PROTAC degradation with dissolving microneedle delivery for OSCC; no clinical trial data, preclinical evidence, or mechanistic validation is presented.
Retrospective single-center cohort confirming that CDK4/6 inhibitors with endocrine therapy produce PFS and OS outcomes consistent with pivotal trials in HR+/HER2− metastatic breast cancer, but lacks the design rigor and sample size for practice guidance beyond established use.
A randomized controlled trial with a clear efficacy signal (higher ORR and pCR with dual-targeted therapy) and favorable tumor marker reduction, but with surrogate endpoints and no hard clinical outcomes reported.
A methodologically sound single-centre internal validation study of prognostic nomograms with good discrimination (C-index 0.74–0.76) in a contemporary HER2-positive metastatic cohort, but limited by lack of specific treatment annotation and short median follow-up relative to the 5-year outcome estimates.
Single-centre retrospective observational study of TDM data identifying associations between TKI concentrations and biochemical parameters, without clinical outcome validation or prospective intervention testing.
First-in-class tri-specific T-cell engager showing promising preclinical efficacy in xenograft models, but lacks human clinical data and relies on surrogate endpoints and animal studies.